Ruo-Jing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ruo-Jing Li has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Jonathon Vallejo
Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD
16 shared publications - Ashley C. Woods
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
11 shared publications - Edwin Chiu Yuen Chow
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. 1
11 shared publications - Jielin Sun
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
11 shared publications - Kelly J. Norsworthy
Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD
11 shared publications - Marc R. Theoret
Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD
11 shared publications
Latest Publications
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Data from FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
On May 25, 2022, FDA approved a supplemental application for ivosidenib (Tibsovo; Servier) extending the indication in patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in older adults or those with comorbidities to include the combination with azacitidine. The efficacy of ivosidenib in combination with azacitidine was evaluated in Study AG120-C-009, a phase 3, multicenter, double-blind, randomized (1:1), controlled study of ivosidenib or matched placebo in combination with azacitidine in adults with previously untreated AML with an IDH1 mutation who were 75 years or older or had comorbidities that precluded use of intensive induction chemotherapy. Efficacy was established on the basis of improved event-free survival and overall survival on the ivosidenib + azacitidine arm [HR, 0.35; 95% confidence interval (CI), 0.17–0.72; P = 0.0038, and HR, 0.44; 95% CI, 0.27–0.73; P = 0.0010], respectively. Furthermore, the rate and duration of complete remission (CR) were improved with ivosidenib versus placebo [CR 47% versus 15%, two-sided P < 0.0001; median duration of CR not estimable (NE; 95% CI, 13.0–NE) months versus 11.2 (95% CI, 3.2–NE) months. The safety profile of ivosidenib in combination with azacitidine was consistent with that of ivosidenib monotherapy, with important adverse reactions including differentiation syndrome (15%) and QT interval prolongation (20%).
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
On May 25, 2022, FDA approved a supplemental application for ivosidenib (Tibsovo; Servier) extending the indication in patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in older adults or those with comorbidities to include the combination with azacitidine. The efficacy of ivosidenib in combination with azacitidine was evaluated in Study AG120-C-009, a phase 3, multicenter, double-blind, randomized (1:1), controlled study of ivosidenib or matched placebo in combination with azacitidine in adults with previously untreated AML with an IDH1 mutation who were 75 years or older or had comorbidities that precluded use of intensive induction chemotherapy. Efficacy was established on the basis of improved event-free survival and overall survival on the ivosidenib + azacitidine arm [HR, 0.35; 95% confidence interval (CI), 0.17–0.72; P = 0.0038, and HR, 0.44; 95% CI, 0.27–0.73; P = 0.0010], respectively. Furthermore, the rate and duration of complete remission (CR) were improved with ivosidenib versus placebo [CR 47% versus 15%, two-sided P < 0.0001; median duration of CR not estimable (NE; 95% CI, 13.0–NE) months versus 11.2 (95% CI, 3.2–NE) months. The safety profile of ivosidenib in combination with azacitidine was consistent with that of ivosidenib monotherapy, with important adverse reactions including differentiation syndrome (15%) and QT interval prolongation (20%).
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Preferred Terms included in grouped terms
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Preferred Terms included in grouped terms
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Preferred Terms included in grouped terms
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Preferred Terms included in grouped terms
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Event-Free Survival by Subgroup
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Event-Free Survival by Subgroup
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Event-Free Survival by Subgroup
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Event-Free Survival by Subgroup
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Frequent Laboratory Abnormalities
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Frequent Laboratory Abnormalities
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Frequent Laboratory Abnormalities
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Frequent Laboratory Abnormalities
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Data from FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
On May 25, 2022, FDA approved a supplemental application for ivosidenib (Tibsovo; Servier) extending the indication in patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in older adults or those with comorbidities to include the combination with azacitidine. The efficacy of ivosidenib in combination with azacitidine was evaluated in Study AG120-C-009, a phase 3, multicenter, double-blind, randomized (1:1), controlled study of ivosidenib or matched placebo in combination with azacitidine in adults with previously untreated AML with an IDH1 mutation who were 75 years or older or had comorbidities that precluded use of intensive induction chemotherapy. Efficacy was established on the basis of improved event-free survival and overall survival on the ivosidenib + azacitidine arm [HR, 0.35; 95% confidence interval (CI), 0.17–0.72; P = 0.0038, and HR, 0.44; 95% CI, 0.27–0.73; P = 0.0010], respectively. Furthermore, the rate and duration of complete remission (CR) were improved with ivosidenib versus placebo [CR 47% versus 15%, two-sided P < 0.0001; median duration of CR not estimable (NE; 95% CI, 13.0–NE) months versus 11.2 (95% CI, 3.2–NE) months. The safety profile of ivosidenib in combination with azacitidine was consistent with that of ivosidenib monotherapy, with important adverse reactions including differentiation syndrome (15%) and QT interval prolongation (20%).
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
On May 25, 2022, FDA approved a supplemental application for ivosidenib (Tibsovo; Servier) extending the indication in patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in older adults or those with comorbidities to include the combination with azacitidine. The efficacy of ivosidenib in combination with azacitidine was evaluated in Study AG120-C-009, a phase 3, multicenter, double-blind, randomized (1:1), controlled study of ivosidenib or matched placebo in combination with azacitidine in adults with previously untreated AML with an IDH1 mutation who were 75 years or older or had comorbidities that precluded use of intensive induction chemotherapy. Efficacy was established on the basis of improved event-free survival and overall survival on the ivosidenib + azacitidine arm [HR, 0.35; 95% confidence interval (CI), 0.17–0.72; P = 0.0038, and HR, 0.44; 95% CI, 0.27–0.73; P = 0.0010], respectively. Furthermore, the rate and duration of complete remission (CR) were improved with ivosidenib versus placebo [CR 47% versus 15%, two-sided P < 0.0001; median duration of CR not estimable (NE; 95% CI, 13.0–NE) months versus 11.2 (95% CI, 3.2–NE) months. The safety profile of ivosidenib in combination with azacitidine was consistent with that of ivosidenib monotherapy, with important adverse reactions including differentiation syndrome (15%) and QT interval prolongation (20%).